CME: Severe Uncontrolled Asthma: Assessing Phenotypic-driven Approaches to Treatment

Released: December 18, 2018     Valid for credit through: December 17, 2019

 

Activity Overview

 

An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to standard therapies. While there are still no widely accepted definitions of phenotypes in severe asthma, guidelines from the European Respiratory Society and American Thoracic Society suggest that there may be certain characteristics, such as eosinophilic airway inflammation, that may guide health care professionals to tailor a more individualized, targeted treatment approach. In this live satellite symposium, experts in the field will evaluate asthma phenotypes and their implications for the treatment of severe uncontrolled asthma, as well as assess pertinent clinical studies utilizing monoclonal antibodies that target key immunologic mediators in severe asthma. The program will also feature the Wheel of Knowledge, a gaming segment that will reinforce topics discussed in the preceding didactic presentations.

Estimated Time To Complete: 60 minutes

Continue to Activity 


By clicking "Continue to Activity" you attest that you have read and understood the CME required elements.

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Allergy, Asthma & Immunology https://t.co/bz6W0CS4gd, see more https://t.co/CpGiFv6pPL
1hreplyretweetfavorite
Interasma RT @EAACI_HQ: Are you going to #EAACI2019? Tell us what you are most looking forward to ! #EAACI #allergy #immunology #lisbon #research #…
13hreplyretweetfavorite
Interasma RT @ACAAI: Sometimes, an allergist may recommend an elimination diet to help pinpoint the food that you or your child might be sensitive to…
13hreplyretweetfavorite
Interasma RT @AllergyEaaci: Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due…
13hreplyretweetfavorite
Interasma RT @AllergyEaaci: Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with Chronic Urticaria. Corresp…
13hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma